These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
194 related articles for article (PubMed ID: 36788737)
1. Targeting of SIRPα as a potential therapy for Langerhans cell histiocytosis. Okamoto T; Murata Y; Hasegawa D; Yoshida M; Tanaka D; Ueda T; Hazama D; Oduori OS; Komori S; Takai T; Saito Y; Kotani T; Kosaka Y; Maniwa Y; Matozaki T Cancer Sci; 2023 May; 114(5):1871-1881. PubMed ID: 36788737 [TBL] [Abstract][Full Text] [Related]
2. Circulating CD1c+ myeloid dendritic cells are potential precursors to LCH lesion CD1a+CD207+ cells. Lim KPH; Milne P; Poidinger M; Duan K; Lin H; McGovern N; Abhyankar H; Zinn D; Burke TM; Eckstein OS; Chakraborty R; Sengal A; Scull B; Newell E; Merad M; McClain KL; Man TK; Ginhoux F; Collin M; Allen CE Blood Adv; 2020 Jan; 4(1):87-99. PubMed ID: 31899802 [TBL] [Abstract][Full Text] [Related]
3. RAF/MEK/extracellular signal-related kinase pathway suppresses dendritic cell migration and traps dendritic cells in Langerhans cell histiocytosis lesions. Hogstad B; Berres ML; Chakraborty R; Tang J; Bigenwald C; Serasinghe M; Lim KPH; Lin H; Man TK; Remark R; Baxter S; Kana V; Jordan S; Karoulia Z; Kwan WH; Leboeuf M; Brandt E; Salmon H; McClain K; Poulikakos P; Chipuk J; Mulder WJM; Allen CE; Merad M J Exp Med; 2018 Jan; 215(1):319-336. PubMed ID: 29263218 [TBL] [Abstract][Full Text] [Related]
4. BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups. Berres ML; Lim KP; Peters T; Price J; Takizawa H; Salmon H; Idoyaga J; Ruzo A; Lupo PJ; Hicks MJ; Shih A; Simko SJ; Abhyankar H; Chakraborty R; Leboeuf M; Beltrão M; Lira SA; Heym KM; Bigley V; Collin M; Manz MG; McClain K; Merad M; Allen CE J Exp Med; 2014 Apr; 211(4):669-83. PubMed ID: 24638167 [TBL] [Abstract][Full Text] [Related]
5. CSF1R Is Required for Differentiation and Migration of Langerhans Cells and Langerhans Cell Histiocytosis. Lonardi S; Scutera S; Licini S; Lorenzi L; Cesinaro AM; Gatta LB; Castagnoli C; Bollero D; Sparti R; Tomaselli M; Medicina D; Calzetti F; Cassatella MA; Facchetti F; Musso T; Vermi W Cancer Immunol Res; 2020 Jun; 8(6):829-841. PubMed ID: 32238382 [TBL] [Abstract][Full Text] [Related]
6. BRAFV600E mutant protein is expressed in cells of variable maturation in Langerhans cell histiocytosis. Sahm F; Capper D; Preusser M; Meyer J; Stenzinger A; Lasitschka F; Berghoff AS; Habel A; Schneider M; Kulozik A; Anagnostopoulos I; Müllauer L; Mechtersheimer G; von Deimling A Blood; 2012 Sep; 120(12):e28-34. PubMed ID: 22859608 [TBL] [Abstract][Full Text] [Related]
7. BRAFV600E and MAP2K1 mutations in Langerhans cell histiocytosis occur predominantly in children. Zeng K; Ohshima K; Liu Y; Zhang W; Wang L; Fan L; Li M; Li X; Wang Z; Guo S; Yan Q; Guo Y Hematol Oncol; 2017 Dec; 35(4):845-851. PubMed ID: 27597420 [TBL] [Abstract][Full Text] [Related]
8. Cell-specific gene expression in Langerhans cell histiocytosis lesions reveals a distinct profile compared with epidermal Langerhans cells. Allen CE; Li L; Peters TL; Leung HC; Yu A; Man TK; Gurusiddappa S; Phillips MT; Hicks MJ; Gaikwad A; Merad M; McClain KL J Immunol; 2010 Apr; 184(8):4557-67. PubMed ID: 20220088 [TBL] [Abstract][Full Text] [Related]
9. Bone marrow-derived myeloid progenitors as driver mutation carriers in high- and low-risk Langerhans cell histiocytosis. Xiao Y; van Halteren AGS; Lei X; Borst J; Steenwijk E; de Wit T; Grabowska J; Voogd R; Kemps P; Picarsic J; van den Bos C; Borst J Blood; 2020 Nov; 136(19):2188-2199. PubMed ID: 32750121 [TBL] [Abstract][Full Text] [Related]